Original article
High dosage treatment of nitrogen-containing bisphosphonate ibandronate is required for osseointegration of cementless metal implants

https://doi.org/10.1007/s00776-005-0955-zGet rights and content

Abstract

Background

There is evidence that application of a bisphosphonate can improve fixation of cementless metal implants by enhancing the extent of osseointegration, but the required dose regimen is still under discussion. The current preclinical study was designed to determine the optimal treatment dose of the nitrogen-containing bisphosphonate ibandronate to improve osseointegration of cementless metal implants.

Methods

The study was conducted in 52 female Sprague- Dawley rats in which uncoated and hydroxyapatite-coated titanium implants were surgically inserted into the medullary canal of each femur. The animals were randomly assigned to receive subcutaneous treatment with ibandronate 1 mg/kg body weight (osteoporosis dose) or 25 mg/kg (tumor dose) per day or saline solution for control.

Results

Histomorphometric evaluation revealed a significant enhanced extent of osseointegrated implant surface in the high-dose treatment group for both implants compared to the low-dose group and the control group. No significant differences were observed between the two implants in any group.

Conclusions

The results of the present study indicate that improved osseointegration of hydroxyapatite-coated and uncoated titanium implants is dose-dependent and requires high-dose application of bisphosphonate ibandronate equivalent to that needed to treat patients with tumor disease. Lower doses equivalent to those for treatment of osteoporosis showed no beneficial effect.

References (29)

  • A. Pataki et al.

    Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment

    Anat Rec

    (1997)
  • S.J. Meraw et al.

    Use of alendronate in periimplant defect regeneration

    J Periodontol

    (1999)
  • T. Hennigs et al.

    Dosedependent prevention of early periprosthetic bone loss by alendronate

    Z Orthop

    (2002)
  • T.A. Soininvaara et al.

    Effect of alendronate on periprosthetic bone loss after knee arthroplasty: a one-year, randomized, controlled trial of 19 patients

    Calcif Tissue Int

    (2002)
  • Cited by (0)

    View full text